Carisma Therapeutics (CARM) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CARM Hot Sheet
Join SI Premium – FREE
Carisma Therapeutics (NASDAQ: CARM) reported Q3 EPS of ($0.53), $0.04 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $3.83 million versus the consensus estimate of $1.1 million.
For earnings history and earnings-related data on Carisma Therapeutics (CARM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- Viemed Healthcare, Inc. (VMD) Misses Q3 EPS by 2c; updates guidance
- North American Construction (NOA) Misses Q3 EPS by 27c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
